MGMT and central nervous system cancer: Because DSF bears several properties, including the ability to cross the blood-brain barrier (BBB) [13], cytotoxicity against glioma stem cells [14], inhibition of various targets, including the MGMT and ALDH [15], there is significant interest in developing DSF for brain tumor treatment; in fact, a clinical trial has already been listed [16].